Awakn Life Sciences ( (TSE:AWKN) ) has shared an announcement.
Awakn Life Sciences Corp. announced a successful Pre-Investigational New Drug meeting with the FDA regarding its AWKN-002, a treatment for alcohol use disorder. The FDA supports Awakn’s development strategy and confirmed that the company can proceed to Phase 2b clinical trials without additional data, marking a significant milestone in addressing the substantial unmet medical need for effective AUD treatments.
More about Awakn Life Sciences
Awakn Life Sciences Corp. is a clinical-stage biotechnology company that focuses on developing therapeutics for substance use and mental health disorders. The company is involved in creating a proprietary oral thin film formulation of esketamine, targeting alcohol use disorder, aiming to address significant unmet medical needs in the market.
YTD Price Performance: 0%
Average Trading Volume: 24,714
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.74M
For detailed information about AWKN stock, go to TipRanks’ Stock Analysis page.